{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T09:13:59Z","timestamp":1790154839501,"version":"4.0.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1038\/gt.2017.79","type":"journal-article","created":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T13:41:10Z","timestamp":1504791670000},"page":"539-541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Market access of Spinraza (Nusinersen) for spinal muscular atrophy: intellectual property rights, pricing, value and coverage considerations"],"prefix":"10.1038","volume":"24","author":[{"given":"S","family":"Simoens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I","family":"Huys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,7]]},"reference":[{"key":"BFgt201779_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(80)90847-8","volume":"1","author":"J Pearn","year":"1980","unstructured":"Pearn J . Classification of spinal muscular atrophies. Lancet 1980; 1: 919\u2013922.","journal-title":"Lancet"},{"key":"BFgt201779_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1006\/geno.1996.0147","volume":"32","author":"L Burglen","year":"1996","unstructured":"Burglen L, Lefebvre S, Clermont O, Burlet P, Viollet L, Cruaud C et al. Structure and organization of the human survival motor neurone (SMN) gene. Genomics 1996; 32: 479\u2013482.","journal-title":"Genomics"},{"key":"BFgt201779_CR3","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/S0140-6736(08)60921-6","volume":"371","author":"MR Lunn","year":"2008","unstructured":"Lunn MR, Wang CH . Spinal muscular atrophy. Lancet 2008; 371: 2120\u20132133.","journal-title":"Lancet"},{"key":"BFgt201779_CR4","unstructured":"ATMP Regulation. Regulation (EC) No 1394\/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001\/83\/EC and Regulation (EC) No 726\/2004."},{"key":"BFgt201779_CR5","unstructured":"European Medicines Agency. First medicine for spinal muscular atrophy. April 2017. Availavle at: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2017\/04\/news_detail_002735.jsp&mid=WC0b01ac058004d5c1."},{"key":"BFgt201779_CR6","unstructured":"Picchi A . The cost of Biogen\u2019s new drug: $750000 per patient. CBS News 29 December 2016. Available at http:\/\/www.cbsnews.com\/news\/the-cost-of-biogens-new-drug-spinraza-750000-per-patient\/."},{"key":"BFgt201779_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1172-6-42","volume":"6","author":"S Simoens","year":"2011","unstructured":"Simoens S . Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis 2011; 6: 42.","journal-title":"Orphanet J Rare Dis"},{"key":"BFgt201779_CR8","unstructured":"Nace M . FDA approves Biogen\u2019s Spinraza (nusinersen) as first approved SMA drug for children, adults. SMA News Today 2016."},{"key":"BFgt201779_CR9","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/nrd3275","volume":"9","author":"E Tambuyzer","year":"2010","unstructured":"Tambuyzer E . Rare diseases, orphan drugs and their regulation: questions and misconceptions. Nat Rev Drug Discov 2010; 9: 921\u2013929.","journal-title":"Nat Rev Drug Discov"},{"key":"BFgt201779_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nbt.3783","volume":"35","author":"C Morrison","year":"2017","unstructured":"Morrison C . Fresh from the biotech pipeline-2016. Nat Biotechnol 2017; 35: 108\u2013112.","journal-title":"Nat Biotechnol"},{"key":"BFgt201779_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1750-1172-7-74","volume":"7","author":"W Hughes-Wilson","year":"2012","unstructured":"Hughes-Wilson W, Palma A, Schuurman A, Simoens S . Paying for the orphan drug system: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? Orphanet J Rare Dis 2012; 7: 74.","journal-title":"Orphanet J Rare Dis"},{"key":"BFgt201779_CR12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.jval.2013.10.002","volume":"16","author":"J Sussex","year":"2013","unstructured":"Sussex J, Rollet P, Garau M, Schmitt C, Kent A, Hutchings A . A pilot study of multicriteria decision analysis for valuing orphan medicines. Value Health 2013; 16: 1163\u20131169.","journal-title":"Value Health"},{"key":"BFgt201779_CR13","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1038\/nbt1016-1002","volume":"34","author":"K Garber","year":"2016","unstructured":"Garber K . Big win possible for Ionis\/Biogen antisense drug in muscular atrophy. Nature Biotechnol 2016; 34: 1002\u20131003.","journal-title":"Nature Biotechnol"},{"key":"BFgt201779_CR14","unstructured":"Cure SMA Report, Winter 2016. Available at: http:\/\/www.curesma.org\/documents\/support\u2014care-documents\/2016-winter-directions.pdf."},{"key":"BFgt201779_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/nn.4508","volume":"20","author":"DR Corey","year":"2017","unstructured":"Corey DR . Nusinersen, an antisense oligonucleotide drug for spinal muscular atrophy. Nature Neuroscience 2017; 20: 497\u2013499.","journal-title":"Nature Neuroscience"},{"key":"BFgt201779_CR16","unstructured":"Biogen Press Release 2016. Available at: http:\/\/media.biogen.com\/press-release\/investor-relations\/biogen-and-ionis-pharmaceuticals-report-nusinersen-meets-primary-en."},{"key":"BFgt201779_CR17","unstructured":"Ionis Pharmaceuticals 2016. Available at: http:\/\/www.prnewswire.com\/news-releases\/spinraza-nusinersen-approved-in-us-to-treat-broad-range-of-patients-with-spinal-muscular-atrophy-300383512.html."},{"key":"BFgt201779_CR18","unstructured":"SMA Europe Announcement. Available at: http:\/\/www.sma-europe.eu\/news\/spinraza-community-update-by-biogen-feedback-on-a-call-with-sma-europe\/."},{"key":"BFgt201779_CR19","doi-asserted-by":"crossref","DOI":"10.57598\/R271C","volume-title":"Future scenarios about drug development and drug pricing","author":"P Vandenbroeck","year":"2016","unstructured":"Vandenbroeck P, Raeymakers P, Wickert R, Becher K, Goossens J, Cleemput I et al. Future scenarios about drug development and drug pricing. Health Services Research (HSR) Belgian Health Care Knowledge Centre (KCE): Brussels, 2016, KCE Reports 271. Available at: https:\/\/kce.fgov.be\/publication\/report\/future-scenarios-about-drug-development-and-drug-pricing#.WLKeSrGZOCQ."},{"key":"BFgt201779_CR20","unstructured":"TRIPS, Agreement on trade-related aspects of intellectual property rights, 1994. Available at: https:\/\/www.wto.org\/english\/docs_e\/legal_e\/27-trips.pdf."},{"key":"BFgt201779_CR21","doi-asserted-by":"crossref","unstructured":"Anastasaki E, Bradshaw SE, Walker A . An update on market access for advanced-therapy medicinal products in Europe. ISPOR 17th Annual European Congress. ISPOR: Amsterdam, The Netherlands, 2014.","DOI":"10.1016\/j.jval.2014.08.1176"},{"key":"BFgt201779_CR22","doi-asserted-by":"publisher","first-page":"31036","DOI":"10.3402\/jmahp.v4.31036","volume":"4","author":"E Hanna","year":"2016","unstructured":"Hanna E, R\u00e9muzat C, Auquier P, Toumi M . Advanced therapy medicinal products: current and future perspectives. J Market Access Health Policy 2016; 4: 31036.","journal-title":"J Market Access Health Policy"},{"key":"BFgt201779_CR23","first-page":"10","volume":"2","author":"F Lucas","year":"2016","unstructured":"Lucas F . Performance-based managed entry agreements for medicines: much needed, but not feasible? Value & Outcomes Spotlight 2016; 2: 10\u201312.","journal-title":"Value & Outcomes Spotlight"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/gt201779.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/gt201779","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/gt.2017.79","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/gt201779.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T16:37:34Z","timestamp":1750869454000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/gt201779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["BFgt201779"],"URL":"https:\/\/doi.org\/10.1038\/gt.2017.79","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"7 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS and IH are the founders of the KU Leuven Fund on Market Analysis of Biologics and Biosimilars following Loss of Exclusivity (MABEL), in which Biogen participates. The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}